Ankyra Therapeutics Announces $45 Million Series B Financing And Appoints Howard L. Kaufman M.D. As Chief Medical Officer
Ankyra Therapeutics Announces $45 Million Series B Financing And Appoints Howard L. Kaufman M.D. As Chief Medical Officer
11/12/21, 1:00 PM
Location
bostonMoney raised
$45 million
Round Type
series b
Ankyra Therapeutics, a company developing cancer therapies based on tumor localized immune potentiating agents that boost anti-tumor immune responses, today announced the closing of a $45 million Series B financing. Proceeds from the financing will be used to progress Ankyra’s lead molecule, ANK-101 through Investigational New Drug (IND) enabling studies and into Phase 1 clinical trials, as well as advance additional cytokine programs.
Company Info
Location
boston, massachusetts, united states
Additional Info
Ankyra Therapeutics is a biotechnology company that has developed a highly differentiated technology platform that expands the therapeutic window of cytokine drugs by forming a stable depot in the tumor after local administration leading to prolonged immune activation and potent local and systemic immunity with reduced systemic toxicity.